“Coombs disease” is not a single disease but a term people use to describe conditions detected by the Coombs test, a blood test that identifies antibodies attacking red blood cells. The most common condition it diagnoses is autoimmune hemolytic anemia (AIHA), where your immune system mistakenly destroys your own red blood cells. The Coombs test is also used to detect Rh incompatibility between a pregnant mother and her baby, a condition called hemolytic disease of the newborn.
What the Coombs Test Actually Detects
The Coombs test looks for antibodies that target red blood cells. There are two versions, each answering a different question.
The direct Coombs test checks whether antibodies are already stuck to your red blood cells right now. A blood sample is washed in saline to isolate the red blood cells, then a special reagent is added. If the cells clump together, antibodies are present and actively marking those cells for destruction. This version is the one used to diagnose autoimmune hemolytic anemia.
The indirect Coombs test checks for antibodies floating freely in your blood that could attach to red blood cells later. It’s primarily used in two situations: screening before a blood transfusion to make sure donated blood won’t trigger a reaction, and during prenatal care to check whether a pregnant woman has developed antibodies against her baby’s blood type.
Autoimmune Hemolytic Anemia
AIHA is the condition most closely associated with a positive direct Coombs test. Your immune system produces antibodies that latch onto your own red blood cells, flagging them for destruction. Your body breaks these cells down faster than your bone marrow can replace them, leading to anemia.
Symptoms include unusual fatigue, weakness, rapid heartbeat, shortness of breath, yellowing of the skin or eyes (jaundice), dark urine, and an enlarged spleen. These develop because red blood cells carry oxygen throughout your body, and when they’re destroyed too quickly, every organ feels the shortage. The jaundice and dark urine come from a waste product called bilirubin, which builds up as red blood cells break apart.
Warm and Cold Types
AIHA comes in two forms based on the temperature at which the antibodies become active. Warm AIHA is the more common type. The antibodies (IgG type) attack red blood cells at normal body temperature, around 98.6°F. Cold AIHA involves a different antibody (IgM) that activates when blood cools below core body temperature, such as in your fingers, toes, or ears in cold weather. Cold AIHA is sometimes called cold agglutinin disease.
What Triggers It
In many cases, AIHA appears without an obvious cause. This is called idiopathic AIHA. But it can also be triggered by other conditions or medications. Certain cancers, autoimmune disorders like lupus, and viral infections are known triggers. Some medications can also set it off. The most commonly implicated drugs include certain antibiotics (particularly cefotetan, ceftriaxone, and piperacillin) and the cancer drug fludarabine, which is the single most common medication linked to AIHA.
How It’s Treated
First-line treatment typically involves steroids to suppress the immune system’s attack on red blood cells. In severe cases, immunoglobulin may be given intravenously alongside the steroids, and blood transfusions are used when the anemia becomes dangerous. Patients with severe hemolysis also receive blood-thinning medication to prevent clots, since the destruction of red blood cells raises clotting risk.
If steroids don’t work or the disease comes back, rituximab (a targeted immune therapy) has become the preferred second-line option. It works by reducing the immune cells responsible for producing the harmful antibodies. Surgical removal of the spleen, once the standard backup plan, is now reserved for later stages when other treatments have failed.
Hemolytic Disease of the Newborn
The other major condition linked to the Coombs test involves a mismatch between a mother’s blood type and her baby’s. When an Rh-negative mother carries an Rh-positive baby, fetal red blood cells can cross the placenta into the mother’s bloodstream. Her immune system recognizes the Rh protein on those cells as foreign and produces antibodies against it. These antibodies then cross back through the placenta and attack the baby’s red blood cells.
This rarely causes problems in a first pregnancy because the mother’s immune system needs time to build up antibodies. The danger grows with subsequent pregnancies, when the immune response is faster and stronger. The destruction of the baby’s red blood cells causes anemia and a buildup of bilirubin. In the baby’s developing brain, high bilirubin levels can cause a condition called kernicterus, which leads to hearing loss, involuntary movements, visual problems, and cerebral palsy.
Prevention With Anti-D Injections
This condition is largely preventable. Rh-negative mothers receive an injection of anti-D immunoglobulin (commonly known by the brand name RhoGAM) at 26 to 28 weeks of pregnancy and again within 72 hours of delivering an Rh-positive baby. This injection works by neutralizing any fetal red blood cells in the mother’s bloodstream before her immune system can mount a response. With this schedule, the chance of the mother developing harmful antibodies drops to less than 1%.
Treatment for Affected Newborns
When prevention fails or the condition goes undetected, affected newborns are treated with phototherapy, a special blue light that helps break down bilirubin in the skin. If bilirubin levels keep climbing despite intensive phototherapy, or if the baby shows signs of brain involvement, an exchange transfusion may be needed. This procedure gradually replaces the baby’s blood to remove the harmful antibodies and excess bilirubin. The typical hospital stay for affected newborns runs about a week, and most require one to three red blood cell transfusions during that time.
What a Positive Coombs Test Means
A positive result on a direct Coombs test confirms that antibodies are attached to your red blood cells, but it doesn’t tell you why. The next step is figuring out whether the cause is an autoimmune process, a drug reaction, a transfusion reaction, or something else entirely. A positive indirect Coombs test during pregnancy signals that the mother has developed antibodies that could harm the baby, prompting closer monitoring for the rest of the pregnancy.
Not every positive Coombs test leads to serious illness. Some people have a weakly positive result without significant red blood cell destruction. The test is a starting point for diagnosis, not a diagnosis by itself. What matters is whether the antibodies it detects are actively causing harm, which is determined by looking at the full picture: symptoms, blood counts, and bilirubin levels together.